Introduction of faecal calprotectin testing into the UK inflammatory bowel disease diagnostic pathway reduces environmental burden

Emily Archer Goode, Amy Swanston, John Bridgewood, Henry Swales, Antony Wright, Lindsay Nicholson

Maverex Limited, Newcastle upon Tyne, UK

HSD16



2 OBJECTIVE



 Inflammatory bowel diseases (IBD), such as Crohn's disease and ulcerative colitis, are chronic inflammatory diseases of the gastrointestinal tract.¹

- The prevalence of IBD is rising,² making timely and improved diagnosis increasingly important.
- The IBD diagnosis pathway involves several diagnostic tests and substantial use of

This study aims to quantify GHG emissions associated with the UK IBD diagnosis pathway with and without FCP testing.

Figure 1. The recommended use of faecal calprotectin testing in the UK IBD diagnosis pathway according to published guidelines^{6,7}


Primary care

Secondary care

physician time and healthcare resources.^{3,4}

BACKGROUND

- Faecal calprotectin (FCP) testing for IBD diagnosis in the primary care setting is recommended by the National Institute for Health and Care Excellence (NICE) (DG11)⁵ and by IBD UK¹ (Figure 1).^{6,7} However, uptake in clinical practice has been limited.^{8,9}
- The United Kingdom (UK) has set targets to decarbonise the National Health Service and achieve net-zero by 2030–2045.^{10–12} Sustainable changes to clinical practice that maintain or enhance patient outcomes while reducing environmental impact are crucial to achieving this goal.
- The use of FCP testing in the diagnosis of IBD reduces secondary care referrals and endoscopic investigations,^{13–15} with potential concomitant savings of greenhouse gas (GHG) emissions.



CT, computed tomography; FCP, faecal calprotectin; GP, general practitioner; IBD, inflammatory bowel disease; IBS, irritable bowel syndrome; MRI, magnetic resonance imaging; UK, United Kingdom; 2WW, 2 week wait.






 The UK IBD diagnosis pathway was mapped over one-year according to current clinical practice and published guidelines (Figure 2).^{3,6}

Study limitations

Pre-diagnosis hospitalisation is one of the most significant contributors to carbon dioxide equivalents (CO₂e) in the IBD diagnosis pathway. However, this was not captured in this model due to a lack of published data on the potential reduction in pre-diagnosis hospitalisation following FCP testing implementation.

Figure 2. Study boundary diagram depicting the inclusions and exclusions of the model.^{21–26}



 Changes in secondary care referrals and diagnostic imaging tests following the adoption of FCP testing in the primary care setting were derived from published literature (Table 1).^{1,13,15–18}


Table 1. Greenhouse gas emissions (kg CO₂ equivalents) per healthcare resource use event associated with IBD diagnosis according to published literature

Healthcare resource	Greenhouse gas emissions per visit/ event (kg CO ₂ e)	Associated patient travel (kg CO ₂ e)	Total Greenhouse gas emissions per visit/ event (kg CO ₂ e)
GP visit ²¹	1.14	1.12	2.26
A&E visit only ²¹	13.77	16.42	30.20
A&E plus inpatient stay*21	241.19	16.42	257.61
Specialist care visit ²¹	1.14	5.80	6.94
Endoscopy ^{21,25,26}	16.92	5.80	22.72
Other imaging (MRI, CT, ultrasound) ^{21–24}	11.01	5.80	16.81

- Data on the potential change in diagnostic imaging usage (other than endoscopic investigation) with FCP testing was also not captured in this study.
- Where UK data was unavailable, data from other countries were used as proxies.

A&E, accident and emergency; CT, computed tomography; GP, general practitioner; ICU, intensive care unit; MRI, magnetic resonance imaging.

*Carbon cost for one visit to ER plus an average hospital stay of 6 days per patient per visit.²⁷





- The total GHG emissions associated with the IBD diagnosis pathway without FCP testing over one-year in the UK was estimated at 4,606 tonnes of CO₂e (Table 2).
- Published literature suggests that implementation of FCP testing in primary care could reduce secondary care referrals by **53.73%**, and endoscopic investigations by **48.37%**.

Table 2. Total greenhouse gas emissions (CO² equivalents) per healthcare resource use prior to IBD diagnosis over a one-year time period according to published literature


Healthcare resource	Total greenhouse gas emissions per visit/ event (kg CO ₂ e)	Total number of annual visits/ events	Total greenhouse gas emissions annually (kg CO ₂ e)	Total greenhouse gas emissions annually (tonnes CO ₂ e)	
GP visit ^{21,28}	2.26	21,030.57	47,457.58	47.46	
A&E visit only ^{1,21,29}	30.20	24,184.43	730,287.64	3,250.39	
A&E plus inpatient stay*1,21,29	257.61	9,782.47	2,520,106.38		
Specialist care visit ^{21,28}	6.94	72,270.00	501,308.08	501.31	
Endoscopy ^{21,25,26,28}	22.72	20,596.95	467,859.72	807.28	
Other imaging (MRI, CT, ultrasound) ^{21–24,28}	16.81	20,187.42	339,417.82		
Total			4,606,437.23	4,606.44	

 Following NICE recommendations to implement FCP testing could reduce GHG emissions by 495.66 tonnes CO₂e annually; which is equivalent to a 10.76% reduction in CO₂e compared to the UK IBD diagnostic pathway without FCP testing (Figure 3).

This GHG saving is comparable to:



Figure 3. Implementation of FCP testing in the primary care setting reduces the annual GHG emissions in the UK



*Carbon cost for one visit to ER plus an average hospital stay of 6 days per patient per visit.27

A&E, accident and emergency; CO₂e, carbon dioxide equivalents; CT, computed tomography; GP, general practitioner; IBD, inflammatory bowel disease; kg, kilogram; MRI, magnetic resonance imaging

05 DISCUSSION AND CONCLUSIONS



- FCP testing confers patient benefit by reducing the time to IBD diagnosis and treatment, in addition to avoiding the need for secondary care referrals and invasive biopsy in a high proportion of patients.
- Moreover, implementing FCP testing in the primary care setting substantially reduces GHG emissions by avoiding unnecessary secondary care referrals and endoscopic investigations.
- Optimising care pathways can improve patient outcomes, as well as aiding healthcare systems to meet their net zero targets.

References

1. IBD UK. Crohn's and Colitis Care in the UK: The Hidden Cost and a Vision for Change. Published online April 2021. Accessed September 25, 2024. https://crohnsandcolitis.org.uk/media/k01ojh41/ibd-national-report.pdf. 2. Alatab S et al. The global, regional, and national burden of inflammatory bowel disease in 195 countries and erritories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol. 2020;5(1):17-30. doi:10.1016/S2468-1253(19)30333-4. 3. Lamb CA et al. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut. 2019;68(Suppl 3):s1. doi:10.1136/gutjnl-2019-31848-4. NICE. Scenario: Suspected Crohn's disease, 2024. Accessed September 26, 2024. https://cks.nice.org.uk/topics/crohns-disease/management/suspected-crohns-disease/. 5. NICE. Faecal calprotectin diagnostic tests for inflammatory diseases of the bowel. 2013. Accessed September 26, 2024. https://www.nice.org.uk/guidance/dg11. 6. NICE. Inflammatory bowel disease. Quality standard [QS81]. 2015. Accessed January 10, 2024. https://www.nice.org.uk/guidance/qs81/chapter/Quality-statement-1-Specialist-assessment. 7. NHS. Primary Care nflammatory Bowel Disease Diagnostic Pathway – Faecal Calprotectin (FCp) Testing. https://gp-portal.westhampshireccg.nhs.uk/pathway/primary-car diagnostic-pathway-faecal-calprotectin-fcp-testing/#:~:text=Calprotectin%20is%20a%20protein%20released,calprotectin%20are%20found%20in%20IBD. 8. Hicks A, Hamlin PJ, Seling CP. The Association of Introducing a Faecal Calprotectin Testing Pathway for Suspected Inflammatory Bowel Disease in Primary Care and Time to Diagnosis or Treatment. Inflamm Intest Dis. 2020;5(4):191-199. doi:10.1159/000509907. 9. Freeman K, Ryan R, Parsons N, Taylor-Phillips S, Willis BH, Clarke A. Faecal calprotectin testing in UK general practice: a retrospective cohort study using The Health Improvement Network database. Br J Gen Pract. 2021;71(712):e854. doi:10.3399/BJGP.2021.0125. 10. NHS England. Delivering a 'Net Zero' National Health Service. Published online 2020. Accessed July 10, 2024. https://www.england.nhs.uk/greenernhs/wp-content/uploads/sites/51/2020/10/de service.pdf. 11. NHS Scotland. NHS Scotland climate emergency and sustainability strategy: 2022-2026. Published online 2022. Accessed July 10, 2024 https://www.gov.scot/publications/nhs-scotland-climate-emergency-sustainability-strategy-2022-2026/ 12. NHS Wales. NHS Wales Decarbonisation Strategic Delivery Plan. Published online 2021. Accessed July 10, 2024. https://www.gov.wales/sites/default/files/publications/2021-03/nhs-wales-decarbonisation-strategic-delivery-plan-2021-2030-summary.pdf 13. van Rheenen PF, Van de Vijver E, Fidler V. Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis. BMJ. 2010;341:c3369. doi:10.1136/bmj.c3369 14. Motaganahalli S, Beswick L, Con D, van Langenberg DR. Faecal calprotectin delivers on convenience, cost reduction and clinical decision-making nflammatory bowel disease: a real-world cohort study. Intern Med J. 2019;49(1):94-100. doi:10.1111/imj.14027 15. Walker GJ et al. Faecal calprotectin effectively excludes infla bowel disease in 789 symptomatic young adults with/without alarm symptoms: a prospective UK primary care cohort study. Aliment Pharmacol Ther. 2018;47(8):1103-1116. doi:10.1111/apt.14563 16. NHS. Faecal Calprotectin case study for commissioners. Published online 2018. Accessed September 27, 2024 https://www.nhsbsa.nhs.uk/sites/default/files/2018-06/CCG%20Faecal%20Calprotectin%20case%20study%20(V2)%204%20pager%20-%2006.2018.pdf 17. Kennedy NA et al. Clinica Jtility And Diagnostic Accuracy of Faecal Calprotectin For IBD At First Presentation To Gastroenterology Services In Adults Aged 16-50 Years. J Crohns Colitis. 2015;9(1):41-49. doi:10.1016/j.crohns.2014.07.005 18. Turvill J et al. Evaluation of the clinical and cost-effectiveness of the York Faecal Calprotectin Care Pathway. Frontline Gastroenterol. 2018;9(4):285 doi:10.1136/flgastro-2018-100962 19. Energy Guide. Average Carbon Footprint Per House In The UK. 2023. Accessed September 27, 2024. https://energyguide.org.uk/average-carbor footprint-uk/ 20. Statistica. Carbon footprint of selected modes of transportation in the United Kingdom in 2023. 2023. Accessed September 27, 2024 https://www.statista.com/statistics/1233337/carbon-footprint-of-travel-per-kilometer-by-mode-of-transport-uk/ 21, Sustainable Healthcare Coalition. Sustainable Hea Accessed September 26, 2024. https://shcoalition.org/ 22. McAlister S et al. The carbon footprint of hospital diagnostic imaging in Australia. Lancet Reg Health – West Pac. 2022;24 doi:10.1016/j.lanwpc.2022.100459 23. Esmaeili A, McGuire C, Overcash M, Ali K, Soltani S, Twomey J. Environmental impact reduction as a new dimension for quality me nealthcare services. Int J Health Care Qual Assur. 2018;31(8):910-922. doi:10.1108/IJHCQA-10-2016-0153 24. Martin M, Mohnke A, Lewis GM, Dunnick NR, Keoleian G, Maturen KE Environmental Impacts of Abdominal Imaging: A Pilot Investigation. J Am Coll Radiol. 2018;15(10):1385-1393. doi:10.1016/j.jacr.2018.07.015 25. Lacroute J et al. The carbon footprint of ambulatory gastrointestinal endoscopy. Endoscopy. 2023;55(10):918-926. doi:10.1055/a-2088-4062 26. Elli L et al. The carbon cost of inappropriate endoscopy. Gastrointest Endosc 2024;99(2):137-145.e3. doi:10.1016/j.gie.2023.08.018 27. Lyons M et al. Patterns of emergency admission for IBD patients over the last 10 years in Lothian, Scotland: A retrospective prevalent cohort analysis. Aliment Pharmacol Ther. Published online 2022. doi:doi.org/10.1111/apt.16867 28. Melesse DY et al. Estimates of Disease Course in Inflammatory Bowe Disease Using Administrative Data: A Population-level Study. J Crohns Colitis. 2017;11(5):562-570. doi:10.1093/ecco-jcc//jw201 29. Irving P et al. IBD2020 global forum: results of an international patient survey on guality of care. Intest Res. 2018;16(4):537-545. doi:10.5217/ir.2018.00041

maverex